Avanos Medical Inc.
AVNS evidence brief
What we can confirm
- BioSniper Score:
- 6.9 / 10
- Market Cap:
- $1.17B
- Cash Runway:
- 16.0 mo
What it means
What to watch
Prepared research question
What matters most for AVNS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AVNS
Avanos Medical Inc. is a medical technology company that develops and markets clinically superior device solutions, holding leading market positions in multiple categories globally.
Key risk: Pricing and cost-containment pressures
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2026.
Avanos Medical Inc. is a medical technology company that develops and markets clinically superior device solutions, holding leading market positions in multiple categories globally.
- Avanos is a medical technology company focused on delivering clinically superior medical device solutions [sec_mda · as of 2026-05-05].
- The company holds leading market positions in multiple categories across its portfolio [sec_mda · as of 2026-05-05].
- As of 2026-03-31, Avanos reported cash & equivalents of $65.6M, total revenue of $182.2M, net income of $5.1M, and shareholders' equity of $782.1M [sec].
- Cash and equivalents decreased by $17.9 million to $89.8 million as of December 31, 2025 compared to $107.7 million the prior year [sec_mda · as of 2026-02-24].
- The company is committed to addressing healthcare needs including providing nutrition to patients and reducing opioid use [sec_mda · as of 2026-05-05].
What works
- Avanos holds leading market positions in multiple categories across its portfolio, indicating competitive strength [sec_mda · as of 2026-05-05].
- The company reported positive net income of $5.1M as of 2026-03-31, demonstrating profitability [sec].
- Avanos generated $74.7 million of cash from operating activities in the period ending December 31, 2025, showing operational cash generation [sec_mda · as of 2026-02-24].
What to weigh
- Cash and equivalents decreased by $17.9 million to $89.8 million as of December 31, 2025, driven by capital expenditures, acquisitions, and debt repayments [sec_mda · as of 2026-02-24].
- The company faces pricing pressures and cost-containment measures that could adversely affect product demand and pricing [sec_mda · as of 2026-05-05].
- Forward-looking statements are subject to risks including general economic conditions and weakening demand [sec_mda · as of 2026-05-05].
From the filings
Quoted directly from source documents.
Avanos is a medical technology company focused on clinically superior device solutions
“Avanos is a medical technology company focused on delivering clinically superior medical device solutions that help patients get back to the things that matter.”
SEC MD&A · February 24, 2026
The company holds leading market positions in multiple categories
“We develop, manufacture and market our recognized brands globally and hold leading market positions in multiple categories across our portfolio.”
SEC MD&A · May 5, 2026
Cash and equivalents decreased to $89.8 million as of December 31, 2025
“Cash and equivalents decreased by $17.9 million to $89.8 million as of December 31, 2025 compared to $107.7 million last year.”
SEC MD&A · February 24, 2026
The company faces pricing pressures and cost-containment measures
“pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products”
SEC MD&A · May 5, 2026
Catalyst timeline
- 2026-05-05 · Earnings Report - SEC 8-K filing — Most recent earnings report filed; provides updated financial results and management discussion.
Risks & what to watch (3)›
Key risks
- Pricing and cost-containment pressures — Pricing pressures and cost-containment measures could adversely affect product price or demand [sec_mda · as of 2026-05-05].
- Economic conditions weakening demand — Weakening economic conditions could adversely affect the level of demand for products [sec_mda · as of 2026-05-05].
- Cash decline from acquisitions and capex — Cash decreased $17.9M to $89.8M as of Dec 31, 2025 due to capex, acquisitions, and debt repayments [sec_mda · as of 2026-02-24].
What to watch
- Monitor upcoming earnings reports for financial performance trends; next report expected around August 2026 based on historical pattern [catalyst].
- Watch for updates on the pending merger with certain affiliates of American [sec_mda · as of 2026-05-05].
- Track cash and equivalents levels and debt repayment activities in future filings [sec_mda · as of 2026-02-24].
Sources: Catalysts · Competitor trials · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run Avanos Medical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Avanos Medical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
16.0 months
D/E 0.34 · 2% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Short Interest
as of May 20, 2026- % of float
- 3.5%
- Days to cover
- 0.6
- Shares short
- 1,211,005
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AVNS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Avanos Medical Inc.?
Avanos Medical Inc. is a medical technology company that develops and markets clinically superior device solutions, holding leading market positions in multiple categories globally.
Who is the CEO of Avanos Medical Inc.?
Mr. David C. Pacitti M.B.A. is the chief executive officer of Avanos Medical Inc. (AVNS).
Where is Avanos Medical Inc. headquartered?
Avanos Medical Inc. (AVNS) is headquartered in Alpharetta, GA, United States.
What therapeutic areas does Avanos Medical Inc. focus on?
Avanos Medical Inc. develops therapies across Pain, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.